Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida Blue provider‑administered specialty drugs…
    Ask Trek AI about this page
    CurrentFlorida BluePolicy N/A

    Provider Administered Specialty Drugs

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage, prior authorization, limited distribution, and program contacts for provider-administered specialty drugs under Florida Blue medical benefits; applies to providers and facilities billing these drugs.

    Policy Summary
    PayerFlorida Blue
    PolicyProvider Administered Specialty Drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2021
    Next Review DateN/A
    Key ActionObtain prior authorization when required; coverage may be denied if PA is not obtained.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    dozenslisted specialty drugs or entries
    LDDLimited Distribution Drug flag
    PAPrior Authorization noted

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1-800-727-2227
    provider support

    Coverage Criteria

    Certain drugs may not be covered by all plans. Coverage determinations depend on the member contract benefit and the PA program; providers should refer to the member contract benefit and the Prior Authorization Program Information and Forms to determine whether a listed drug is covered and whether prior authorization is required. Coverage under the medical benefit applies for provider‑administered drugs when noted, but this list is not all‑inclusive and plan variations may exclude specific drugs.

    Provider Actions and Prior Authorization

    Prior Authorization

    Prior Authorization (PA) may be required

    Many provider-administered specialty drugs listed in this index require Prior Authorization (PA). PA applicability and requirements vary by drug and by plan; providers should refer to the Prior Authorization Program Information and Forms and the member contract benefit for specific PA details.

    • PA requirements vary by drug and plan.
    • Refer to the Prior Authorization Program Information and Forms for submission details.
    Step Therapy

    Utilization management (QL and step edits)

    Quantity limits (QL) and other utilization management controls such as step edits may apply for some drugs. This document does not detail specific step therapy rules; check the drug-specific PA guidance or plan documents for any step edits.

    • QL may be indicated for certain drugs (e.g., QL noted for Xolair).
    • Specific step therapy rules are not provided in this index — consult PA guidance or plan documents.
    Documentation Required

    Refer to member contract, PA forms, and PADP for documentation

    Providers must consult the member contract benefit, the Prior Authorization Program Information and Forms, and the Provider Administered Drug Program (PADP) section of the online provider manual to determine required documentation and coverage.

    • Refer to the PADP section for enrollment and dispensing details for provider-administered drugs.
    • Use the Prior Authorization Program Information and Forms to determine documentation required for PA requests.
    Denial Risk

    Obtain PA when required to avoid denial

    Coverage may be denied if Prior Authorization is not obtained when the drug requires PA. Prior authorization requirements may differ by plan; verify PA status before providing or billing for a specialty drug.

    • Failure to obtain PA when required can result in claim denial.
    • Confirm PA requirements against the member contract benefit and PA program materials.

    Background

    This document is an administrative coverage index that lists provider‑administered specialty drugs and indicates their prior authorization (PA) and Limited Distribution Drug (LDD) status where applicable. It does not provide disease‑specific clinical treatment criteria. Providers enrolled in the Provider Administered Drug Program (PADP) should consult the PADP section of the online provider manual for the current list of included drugs. For questions after consulting the table, contact the Provider Contact Center: 1‑800‑727‑2227 or the phone number on the back of the member’s insurance card.

    Definitions

    LDD — Limited Distribution Drug
    DefinitionLimited Distribution Drug (LDD) — Dispensing pharmacy can be found here: Limited Distribution Drugs.
    Where notedLDD designation appears next to specific drug entries in the list (e.g., Rituxan LDD, PA; Spinraza LDD, PA).
    ImplicationLDD drugs may have restricted dispensing through specified specialty pharmacies — refer to the linked Limited Distribution Drugs resource for dispensing pharmacy details.
    PA — Prior Authorization
    DefinitionPrior Authorization (PA) — Authorization required before coverage may be approved for many listed specialty drugs.
    ScopeMany drugs in the list include a 'PA' designation (e.g., Poteligeo PA; Remicade PA; Yescarta PA).

    Quantity Limits (Examples)

    Xolair (example) — QL noted
    Drug exampleXolair — listed with designations: LDD, PA, QL.
    Document noteQuantity Limit is indicated for Xolair but the specific limit value is not provided in this document.
    Action for providersWhen Xolair is prescribed, verify LDD dispensing requirements, obtain prior authorization if required, and check the applicable quantity limit with the PA program or specialty pharmacy resources.

    Site of Care and Benefit Applicability

    Billing Rule

    Bill provider‑administered drugs to the medical benefit (site of care)

    When a specialty drug is provider‑administered it is covered under the medical benefit (office, infusion center, or hospital outpatient) and should be billed as a medical benefit; some drugs are self‑administered or dispensed through specialty pharmacies and site of care may vary — PADP enrollment may affect dispensing.

    • Provider‑administered drugs are billed under the medical benefit (office, infusion center, hospital outpatient).
    • Some drugs are self‑administered or limited distribution—check dispensing pharmacy and PADP guidance.
    Policy Summary
    PayerFlorida Blue
    PolicyProvider Administered Specialty Drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateOct 1, 2021
    Next Review DateN/A
    Key ActionObtain prior authorization when required; coverage may be denied if PA is not obtained.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Prior AuthorizationBackgroundDefinitionsQuantity Limits (Examples)Site of Care and Benefit Applicability
    ConsequenceCoverage may be denied if prior authorization is not obtained when required; requirements vary by drug and plan.
    QL — Quantity Limit
    DefinitionQuantity Limit (QL) — A restriction on the allowed amount or frequency of a drug supply or administration.
    Usage in documentSome drugs are noted with 'QL' on the list where quantity limits apply (e.g., Xolair LDD, PA, QL).
    DetailSpecific numeric QL values are not provided in this document; refer to program-specific quantity limit resources for exact limits.